Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator

This article was originally published in The Gray Sheet

Executive Summary

While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.

You may also be interested in...



NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy

The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.

Stanford Launches Trial Of NeuroPace’s Responsive Neuromodulation To Stop Overeating

The DBSLOC trial will study the feasibility of using NeuroPace’s RNS responsive neuromodulation system to stimulate the nucleus accumbens in order to stop “loss-of-control” eating in people with treatment-refractory obesity, especially those who have failed to respond adequately to gastric bypass surgery.

New Product Briefs

Product news from Cyberonics, TransEnterix Dexcom, Boston Scientific, St. Jude, Medtronic and Roche.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel